DWM
VRTX icon

Drive Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Drive Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$953K Buy
1,919
+228
+13% +$101K 0.17% 104
2026
Q1 		$755K Buy
1,691
+38
+2% +$17.7K 0.16% 119
2025
Q4 		$749K Buy
1,653
+203
+14% +$87.5K 0.15% 118
2025
Q3 		$568K Buy
1,450
+201
+16% +$84K 0.12% 147
2025
Q2 		$556K Buy
1,249
+176
+16% +$81.1K 0.12% 149
2025
Q1 		$520K Sell
1,073
-48
-4% -$22.4K 0.12% 135
2024
Q4 		$451K Buy
1,121
+12
+1% +$5.56K 0.11% 146
2024
Q3 		$516K Buy
1,109
+8
+0.7% +$3.84K 0.13% 124
2024
Q2 		$516K Buy
1,101
+22
+2% +$9.55K 0.14% 128
2024
Q1 		$451K Buy
1,079
+8
+0.7% +$3.38K 0.13% 151
2023
Q4 		$436K Buy
1,071
+50
+5% +$18.5K 0.14% 136
2023
Q3 		$355K Buy
1,021
+91
+10% +$31.8K 0.13% 151
2023
Q2 		$327K Buy
930
+100
+12% +$33.7K 0.12% 161
2023
Q1 		$262K Buy
+830
New +$249K 0.11% 201

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Drive Wealth Management's VRTX Position: Q2 2026 in Review

Drive Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 13% in Q2 2026, buying an estimated $101K and bringing the position to 1,919 shares worth $953K. The position accounts for 0.17% of the portfolio, ranked #104.

Drive Wealth Management first reported a position in VRTX in Q1 2023 and has held it in 14 quarters since. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Drive Wealth Management held 1,919 shares of Vertex Pharmaceuticals worth $953K as of Q2 2026.
  • Drive Wealth Management bought 228 Vertex Pharmaceuticals shares in Q2 2026, an estimated $101K.
  • Vertex Pharmaceuticals made up 0.17% of Drive Wealth Management's portfolio in Q2 2026, its #104 holding.
  • Drive Wealth Management first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • 1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Drive Wealth Management's 13F filing for Q2 2026, filed 22 Jul 2026.